Allogene Therapeutics Financial Statements (ALLO)
|
|
|
|
Report date
|
|
|
23.02.2022 |
28.02.2023 |
14.03.2024 |
13.03.2025 |
12.03.2026 |
|
12.03.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
114.1 |
0.156 |
0.095 |
0.022 |
0.000 |
|
0.000 |
|
Operating Income, bln rub |
|
|
-180.2 |
-335.5 |
-327.7 |
-273.2 |
-206.9 |
|
-209.3 |
|
EBITDA, bln rub |
? |
|
-169.7 |
-321.2 |
-313.1 |
-243.3 |
-194.6 |
|
-181.4 |
|
Net profit, bln rub |
? |
|
-182.1 |
-340.4 |
-327.3 |
-257.6 |
-190.9 |
|
-190.9 |
|
|
OCF, bln rub |
? |
|
-184.8 |
-220.5 |
-237.7 |
-200.3 |
-149.2 |
|
-149.2 |
|
CAPEX, bln rub |
? |
|
21.4 |
5.19 |
1.52 |
0.694 |
0.386 |
|
0.386 |
|
FCF, bln rub |
? |
|
-206.3 |
-225.7 |
-239.2 |
-201.0 |
-149.6 |
|
-149.6 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
294.3 |
321.4 |
327.8 |
273.2 |
194.6 |
|
172.0 |
|
Cost of production, bln rub |
|
|
0.000 |
14.3 |
0.000 |
0.000 |
12.4 |
|
37.3 |
|
R&D, bln rub |
|
|
220.2 |
256.4 |
242.9 |
192.3 |
150.2 |
|
150.2 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.181 |
1.08 |
|
1.08 |
|
|
Assets, bln rub |
|
|
1 051 |
821.6 |
642.8 |
548.7 |
415.9 |
|
415.9 |
|
Net Assets, bln rub |
? |
|
925.2 |
666.9 |
512.2 |
422.2 |
292.5 |
|
292.5 |
|
Debt, bln rub |
|
|
73.1 |
101.1 |
95.1 |
90.8 |
75.0 |
|
83.3 |
|
Cash, bln rub |
|
|
457.3 |
517.3 |
448.7 |
292.5 |
250.2 |
|
250.2 |
|
Net debt, bln rub |
|
|
-384.2 |
-416.2 |
-353.6 |
-201.7 |
-175.2 |
|
-167.0 |
|
|
Ordinary share price, rub |
|
|
14.9 |
6.29 |
3.21 |
2.13 |
1.37 |
|
2.27 |
|
Number of ordinary shares, mln |
|
|
135.8 |
143.1 |
156.9 |
194.8 |
220.6 |
|
220.6 |
|
|
Market cap, bln rub |
|
|
2 026 |
900 |
504 |
415 |
302 |
|
501 |
|
EV, bln rub |
? |
|
1 642 |
484 |
150 |
213 |
127 |
|
334 |
|
Book value, bln rub |
|
|
925 |
667 |
512 |
422 |
293 |
|
293 |
|
|
EPS, rub |
? |
|
-1.34 |
-2.38 |
-2.09 |
-1.32 |
-0.87 |
|
-0.87 |
|
FCF/share, rub |
|
|
-1.52 |
-1.58 |
-1.52 |
-1.03 |
-0.68 |
|
-0.68 |
|
BV/share, rub |
|
|
6.81 |
4.66 |
3.26 |
2.17 |
1.33 |
|
1.33 |
|
|
EBITDA margin, % |
? |
|
-148.8% |
-205 924% |
-329 543% |
-1 106 032% |
|
|
|
|
Net margin, % |
? |
|
-159.6% |
-218 214% |
-344 489% |
-1 170 864% |
|
|
|
|
FCF yield, % |
? |
|
-10.2% |
-25.1% |
-47.5% |
-48.4% |
-49.5% |
|
-29.9% |
|
ROE, % |
? |
|
-19.7% |
-51.0% |
-63.9% |
-61.0% |
-65.3% |
|
-65.3% |
|
ROA, % |
? |
|
-17.3% |
-41.4% |
-50.9% |
-46.9% |
-45.9% |
|
-45.9% |
|
|
P/E |
? |
|
-11.1 |
-2.64 |
-1.54 |
-1.61 |
-1.58 |
|
-2.62 |
|
P/FCF |
|
|
-9.82 |
-3.99 |
-2.11 |
-2.06 |
-2.02 |
|
-3.35 |
|
P/S |
? |
|
17.8 |
5 772 |
5 303 |
18 861 |
|
|
|
|
P/BV |
? |
|
2.19 |
1.35 |
0.98 |
0.98 |
1.03 |
|
1.71 |
|
EV/EBITDA |
? |
|
-9.68 |
-1.51 |
-0.48 |
-0.88 |
-0.65 |
|
-1.84 |
|
Debt/EBITDA |
|
|
2.26 |
1.30 |
1.13 |
0.83 |
0.90 |
|
0.92 |
|
|
R&D/CAPEX, % |
|
|
1 027% |
4 939% |
16 023% |
27 709% |
38 899% |
|
38 899% |
|
|
CAPEX/Revenue, % |
|
|
18.8% |
3 328% |
1 596% |
3 155% |
|
|
|
|
| Allogene Therapeutics shareholders |
